NCT07338721 Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer?
| NCT ID | NCT07338721 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Antalya Training and Research Hospital |
| Condition | Breast Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2026-01-01 with a primary completion date of 2026-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This single-center randomized controlled trial evaluates whether detecting the first lymph node at the axillary entrance with ultrasound guidance, followed by a targeted axillary incision over the pencil-marked projection, improves sentinel lymph node identification compared to the conventional axillary hairline landmark. The study hypothesizes that this technique enables a smaller incision, minimizes tissue dissection, and reduces operative time.
Eligibility Criteria
Inclusion Criteria: * \* Patients with clinical stage T1-T3 disease (tumor ≤5 cm), pN0-pN1 (one to three regional lymph nodes with micrometastases or metastases), and M0 (no distant metastasis) are eligible. Post-neoadjuvant yT1-T3, yN0-yN1, and M0 status are also eligible. All patients are undergoing axillary staging. * Clinically negative axilla * Written informed consent must be obtained prior to inclusio Exclusion Criteria: * Younger than 18 years * Previous breast malignancy * Pregnancy * Pre-operative diagnosis of axillary lymph node metastases * The presence of multiple clinically involved or suspicious lymph nodes * Unable or unwilling to provide informed consent.
Contact & Investigator
Baris R KARAKAS, Assoc. Prof.
PRINCIPAL INVESTIGATOR
Antalya Training and Research Hospital
Frequently Asked Questions
Who can join the NCT07338721 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07338721 currently recruiting?
Yes, NCT07338721 is actively recruiting participants. Visit ClinicalTrials.gov or contact Antalya Training and Research Hospital to inquire about joining.
Where is the NCT07338721 trial being conducted?
This trial is being conducted at Antalya, Turkey (Türkiye).
Who is sponsoring the NCT07338721 clinical trial?
NCT07338721 is sponsored by Antalya Training and Research Hospital. The principal investigator is Baris R KARAKAS, Assoc. Prof. at Antalya Training and Research Hospital. The trial plans to enroll 40 participants.